Ibrutinib/Venetoclax Produces Encouraging Results in Relapsed/ Refractory CLL

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [31] Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma
    Zhiyuan Zhou
    Lei Zhang
    Xinhua Wang
    Xin Li
    Ling Li
    Xiaorui Fu
    Xudong Zhang
    Zhaoming Li
    Zhenchang Sun
    Mingzhi Zhang
    Annals of Hematology, 2021, 100 : 1509 - 1516
  • [32] Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
    Portell, Craig A.
    Wages, Nolan A.
    Kahl, Brad S.
    Budde, Lihua E.
    Chen, Robert W.
    Cohen, Jonathon B.
    Varhegyi, Nikole E.
    Petroni, Gina R.
    Williams, Michael E.
    BLOOD ADVANCES, 2022, 6 (05) : 1490 - 1498
  • [33] Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL
    Ujjani, Chaitra S.
    Wang, Hongkun
    Skarbnik, Alan P.
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD, 2017, 130
  • [34] Ibrutinib and Venetoclax for First-Line Treatment of CLL
    Kater, Arnon P.
    Levin, Mark-David
    Niemann, Carsten U.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (08): : 788 - 789
  • [35] Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study
    Siddiqi, Tanya
    Clay, Pamela
    Murray, Kate
    Shekh, Navshina
    Muir, Alexandra
    Rosen, Steven T.
    Coutre, Steven
    BLOOD, 2021, 138 : 3754 - +
  • [36] Ibrutinib and Venetoclax for First-Line Treatment of CLL
    Jain, Nitin
    Keating, Michael
    Thompson, Philip
    Ferrajoli, Alessandra
    Burger, Jan
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev
    Fowler, Nathan
    Kadia, Tapan
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22): : 2095 - 2103
  • [37] THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY
    Hillmen, P.
    Rawstron, A.
    Munir, T.
    Brock, K.
    Vincente, S. Munoz
    Jefferson, Y.
    Paterson, K.
    Fox, C. P.
    Gribben, J.
    Bloor, A.
    Schuh, A.
    Forconi, F.
    HAEMATOLOGICA, 2017, 102 : 311 - 311
  • [38] The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy
    Munoz-Vicente, Samuel
    Bishop, Rebecca
    Hillmen, Peter
    Munir, Talha
    Rawstron, Andy
    Brock, Kristian
    Fox, Christopher
    Gribben, John
    Bloor, Adrian
    Jefferson, Yolande
    Schuh, Anna
    Forconi, Francesco
    LEUKEMIA & LYMPHOMA, 2017, 58 : 239 - 239
  • [39] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [40] Efficacy of venetoclax as a single agent and in combination with ibrutinib in refractory or relapsed T-prolymphocytic leukaemia
    Kornauth, C.
    Boidol, B.
    Koller, J.
    Ringler, A.
    Van der Kouwe, E.
    Kazianka, L.
    Hoermann, G.
    Simonitsch-Klupp, I
    Jaeger, U.
    Kubicek, S.
    Staber, P. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 272 - 272
12345